| Treatment options in myocarditis and inflammatory cardiomyopathy Focus on i.v. immunoglobulins |
16 |
| Key inflammatory mechanisms underlying heart failure |
11 |
| Cardioprotective effects of irbesartan in polymicrobial sepsis The role of the p38MAPK/NF-kappa B signaling pathway |
7 |
| Palliative care in heart failure A meta-analysis of randomized controlled trials |
6 |
| Removal of epicardial adipose tissue after myocardial infarction improves cardiac function |
5 |
| Association of soluble ST2 with functional capacity in outpatients with heart failure |
5 |
| Left ventricular hypertrabeculation/noncompaction, cardiac phenotype, and neuromuscular disorders |
5 |
| Pulmonary hypertension in HFpEF and HFrEF: Pathophysiology, diagnosis, treatment approaches |
5 |
| Genome-wide DNA methylation patterns in coronary heart disease |
4 |
| Malignant pericardial mesothelioma A systematic review of current practice |
4 |
| Nationwide but still inhomogeneous distribution of certified chest pain units across Germany Need to strengthen rural regions |
4 |
| Efficacy of RADPAD protective drape during coronary angiography |
4 |
| Congestive heart failure caused by silent ischemia and silent myocardial infarction: Diagnostic challenge in type2 diabetes |
4 |
| Peripartum cardiomyopathy |
4 |
| Drug treatment of heart failure in the elderly |
3 |
| Myricetin protects cardiomyocytes from LPS-induced injury |
3 |
| Acute heart failure: An unmet medical need |
3 |
| Cardiac imaging after ischemic stroke: Echocardiography, CT, or MRI? |
3 |
| Plasma osteopontin levels in patients with dilated and hypertrophic cardiomyopathy |
3 |
| Critical inflammatory mechanisms underlying arrhythmias |
3 |
| Cognitive performance of patients with chronic heart failure on sacubitril/valsartan A retrospective cohort study |
3 |
| Device therapy in heart failure with reduced ejection fraction-cardiac resynchronization therapy and more |
3 |
| COPD and heart failure: differential diagnosis and comorbidity |
3 |
| Right ventricular function in pulmonary (arterial) hypertension |
3 |
| European guidelines on lifestyle changes for management of hypertension Awareness and implementation of recommendations among German and European physicians |
3 |
| The right atrium in idiopathic hypereosinophilic syndrome Insights from the 3D speckle tracking echocardiographic MAGYAR-Path Study |
3 |
| ESC/EACTS guidelines onmyocardial revascularization 2018. The most important innovations |
3 |
| Quantitative evaluation of PPAR gamma 2 Pro12Ala polymorphism with hypertension |
3 |
| Effect of remote ischemic postconditioning during thrombolysis in STEMI |
2 |
| Longer-than-average length of stay in acute heart failure Determinants and outcomes |
2 |
| ECG results: tips and tricks for the correct diagnosis. Bradycardia and tachycardia rhythm disorders |
2 |
| Management of pericarditis and pericardial effusion, constrictive and effusive-constrictive pericarditis |
2 |
| Update of the ESC guidelines 2018 on cardiovascular diseases during pregnancy. Most important facts |
2 |
| Management of arterial hypertension. ESC/ESH guidelines 2018 |
2 |
| Non-coding RNA Innovative Regulators with therapeutic Perspective |
2 |
| Cardiac MRI for detecting left atrial/left atrial appendage thrombus in patients with atrial fibrillation Meta-analysis and systematic review |
2 |
| Treatment with 48-mm everolimus-eluting stents Procedural safety and 12-month patient outcome |
2 |
| European dyslipidemia guidelines 2019 What is new? |
2 |
| Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction A retrospective cohort study |
2 |
| Nine-month clinical outcomes in patients with diabetes treated with polymer-free sirolimus-eluting stents and 6-month vs. 12-month dual-antiplatelet therapy (DAPT) |
2 |
| Transcatheter vs. surgical aortic valve replacement and medical treatment Systematic review and meta-analysis of randomized and non-randomized trials |
2 |
| Pulmonary hypertension and valvular heart disease |
2 |
| Left heart function in COPD Impact of lung deflation |
2 |
| Genistein attenuates pathological cardiac hypertrophy in vivo and in vitro |
2 |
| Effect of levosimendan in patients with acute decompensated heart failure A meta-analysis |
2 |
| Coronary restenosis |
2 |
| Improvement of tricuspid regurgitation after transcatheter ASD closure in older patients |
2 |
| Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease. A meta-analysis |
2 |
| Operator radiation exposure during transradial coronary angiography. Effect of single vs. double catheters |
2 |
| Meta-analysis of Fontan procedure Extracardiac conduit vs. intracardiac lateral tunnel |
2 |
